Inclusion Criteria:  HIV-1 infected, 18 years or older On stable & suppressive triple cART for at least 6 months No evidence of resistance to DOR or DTG No laboratory abnormalities, medical/psychiatric conditions or alcohol/drug use considered a barrier to participation by investigators  Women who are pre-menopausal and sexually active should be on one of the following methods of contraception:  Implant Depot injection Intra-uterine device or system Oral hormonal contraception  Exclusion Criteria:  History of virological failure on an NNRTI in absence of a post-failure genotypic resistance test proving absence of resistance to DOR History of virological failure on an INSTI in absence of a post-failure genotypic resistance test proving absence of resistance to DTG (INSTI mutations that will lead to the need of administering DTG twice-daily are considered as resistance to DTG - and the subject will be considered NOT eligible) Concomitant medication contra-indicated with DTG or DOR Haemoglobin <9 g/dL Platelets <80,000/mm3 Creatinine clearance <30 mL/min AST or ALT ≥5N Acute Hepatitis A infection. Concomitant DAA for anti-HCV therapy  Known acute or chronic viral hepatitis B or C.  Individuals testing positive for HBcAb, but negative HBsAg/HBeAg, may be included on the trial. Individuals with positive anti-HCV results, but with HCV RNA not detected may be included on the trial. Pregnant or breastfeeding women